| 101 |
20967300 | Vandetanib: An overview of its clinical development in NSCLC and other tumors. | 2010 Sep |
2 |
| 102 |
19088171 | An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. | 2009 Mar |
2 |
| 103 |
19220256 | Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. | 2009 Jun |
1 |
| 104 |
19318229 | Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines. | 2009 Jun |
1 |
| 105 |
19319137 | Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. | 2009 Apr 21 |
3 |
| 106 |
19332730 | Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. | 2009 May 20 |
3 |
| 107 |
19349511 | Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. | 2009 Apr |
4 |
| 108 |
19362942 | Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy. | 2009 Mar |
1 |
| 109 |
19409038 | A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. | 2009 Apr |
1 |
| 110 |
19447868 | Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. | 2009 May 15 |
1 |
| 111 |
19491268 | Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. | 2009 Jun 15 |
9 |
| 112 |
19512898 | Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. | 2009 Jul |
2 |
| 113 |
19687425 | Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. | 2009 Aug |
2 |
| 114 |
19881951 | The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma. | 2009 Nov |
1 |
| 115 |
19946413 | DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. | 2009 Sep 21 |
1 |
| 116 |
17393165 | Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. | 2008 Feb |
15 |
| 117 |
18177496 | Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib. | 2008 Jan 4 |
1 |
| 118 |
18248788 | EGFR and VEGFR as potential target for biological therapies in HCC cells. | 2008 Apr 18 |
1 |
| 119 |
18364248 | Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. | 2008 Jun 28 |
1 |
| 120 |
18379357 | A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. | 2008 Apr |
2 |
| 121 |
18381602 | Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. | 2008 Sep |
1 |
| 122 |
18520295 | Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer. | 2008 Jun |
3 |
| 123 |
18694994 | Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. | 2008 Aug 15 |
3 |
| 124 |
18936474 | Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. | 2008 Nov 20 |
1 |
| 125 |
21479415 | Antitumor activity of ZD6474 in a metastatic orthotopic brain tumor model. | 2008 May-Jun |
3 |
| 126 |
17203163 | Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. | 2007 Feb |
4 |
| 127 |
17243944 | Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. | 2007 Feb |
1 |
| 128 |
17272980 | Combined targeted therapies in non-small cell lung cancer: a winner strategy? | 2007 Mar |
1 |
| 129 |
17308046 | Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. | 2007 Feb |
3 |
| 130 |
17414626 | Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. | 2007 Jun |
3 |
| 131 |
17631646 | Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. | 2007 Nov 1 |
4 |
| 132 |
17889445 | Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. | 2007 Dec 1 |
2 |
| 133 |
17912240 | ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein. | 2007 Oct 8 |
1 |
| 134 |
17975157 | Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. | 2007 Nov 1 |
1 |
| 135 |
16332356 | ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. | 2006 Feb 14 |
1 |
| 136 |
16377413 | ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. | 2006 Jan 1 |
3 |
| 137 |
16688779 | Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. | 2006 Aug |
3 |
| 138 |
16721126 | Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience. | 2006 Jul |
1 |
| 139 |
16783964 | ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. | 2006 |
2 |
| 140 |
16891475 | Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. | 2006 Jul |
2 |
| 141 |
16937523 | Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects. | 2006 Aug 28 |
1 |
| 142 |
17136225 | Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. | 2006 Oct |
3 |
| 143 |
17145834 | Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. | 2006 Dec 1 |
3 |
| 144 |
17409986 | A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. | 2006 Nov |
2 |
| 145 |
15709198 | Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. | 2005 Feb 1 |
1 |
| 146 |
15867237 | A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. | 2005 May 1 |
3 |
| 147 |
15905307 | Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. | 2005 Aug |
1 |
| 148 |
15928657 | ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. | 2005 Jun |
3 |
| 149 |
16061883 | Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. | 2005 Aug 1 |
1 |
| 150 |
14760102 | Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. | 2004 Jan 15 |
1 |